Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K
4.2K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

17.0K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.3K
2.3K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

9.3K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Cancers·2026
Same author

Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia.

Cell reports·2026
Same author

Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.

Journal for immunotherapy of cancer·2025
Same author

eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small molecules.

Cell reports·2025
Same author

Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems.

Genes & development·2025
Same author

Overcoming impaired antigen presentation in tumor draining lymph nodes facilitates immunotherapy.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Mar 15, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K

Clonal cooperativity in heterogenous cancers.

Hengbo Zhou1, Deepika Neelakantan2, Heide L Ford3

  • 1Program in Cancer Biology, University of Colorado School of Medicine, 12800 East 19th Avenue, Aurora, CO 80045, United States.

Seminars in Cell & Developmental Biology
|September 2, 2016
PubMed
Summary
This summary is machine-generated.

Tumor heterogeneity, driven by diverse cancer cell subclones, promotes tumor growth, metastasis, and resistance to therapy. Targeting the cooperation between these subclones offers a novel therapeutic strategy.

Keywords:
Clonal cooperativityEpithelial to mesenchymal transitionMetastasisTumor heterogeneity

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.8K

Related Experiment Videos

Last Updated: Mar 15, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.8K

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Oncology

Background:

  • Tumor heterogeneity, characterized by diverse genetic and epigenetic alterations and microenvironments, poses a significant challenge in cancer therapy.
  • Intratumor heterogeneity drives competition and cooperation among cancer cell subclones, leading to enhanced tumor progression.

Purpose of the Study:

  • To review recent findings on interclonal interactions within tumors.
  • To explore the therapeutic implications of clonal cooperation in promoting proliferation, metastasis, and therapy resistance.

Main Methods:

  • Literature review of recent studies on tumor heterogeneity and interclonal interactions.
  • Analysis of mechanisms of clonal cooperation (e.g., cell-cell contact, secreted factors).
  • Evaluation of therapeutic strategies targeting clonal cooperation.

Main Results:

  • Cancer cell subclones collaborate to enhance tumor proliferation, metastasis, and resistance to therapies.
  • Interclonal interactions are mediated by cell-cell contact and secreted factors.
  • Targeting key factors involved in clonal cooperation shows therapeutic potential.

Conclusions:

  • Understanding and disrupting clonal cooperation is crucial for overcoming therapeutic resistance.
  • Targeting specific pathways like Wnt and Hedgehog may offer alternative approaches to improve clinical outcomes in cancer treatment.